Began Novartis Pluvicto trial on 4/5/22 after failing ADT+abi, Labs two weeks ago showed PSA dropping from about 25 to 2.4, ALP from mid-300s to 187. That was great to see, but the results of my first bone scan (since starting the trial), done earlier today, are not exactly what I was hoping for:
" There is a new focal area of uptake involving the left aspect of L2. There is increased confluence of radiotracer avid lesions in the mid sternum, intertrochanteric left femur, proximal diaphysis of the right femur, and posterior left 10th rib. Several areas of uptake appear slightly less intense on today's study, for example along the left scapula, sacrum, and T6, T8, and T11 vertebral levels multiple additional areas of uptake elsewhere appear similar "
We are comparing to a bone scan done on 2/23/22, so that was six weeks prior to the first Lu dosing and I suppose there was probably some progression of mets over that time before the current treatment regime. Thoughts?
[Still no pain or other bodily indications, to me, that my bones are riddled with osteoblastic lesions.]
Seems like I'm taking out a few of the PSMA-avid soldiers, but plenty of other PC cells are fat and happy.